These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1152 related items for PubMed ID: 31300482

  • 21. Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes.
    Peeters DJ, van Dam PJ, Van den Eynden GG, Rutten A, Wuyts H, Pouillon L, Peeters M, Pauwels P, Van Laere SJ, van Dam PA, Vermeulen PB, Dirix LY.
    Br J Cancer; 2014 Jan 21; 110(2):375-83. PubMed ID: 24366294
    [Abstract] [Full Text] [Related]

  • 22. In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis.
    Bulfoni M, Gerratana L, Del Ben F, Marzinotto S, Sorrentino M, Turetta M, Scoles G, Toffoletto B, Isola M, Beltrami CA, Di Loreto C, Beltrami AP, Puglisi F, Cesselli D.
    Breast Cancer Res; 2016 Mar 09; 18(1):30. PubMed ID: 26961140
    [Abstract] [Full Text] [Related]

  • 23. Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study.
    Müller V, Riethdorf S, Rack B, Janni W, Fasching PA, Solomayer E, Aktas B, Kasimir-Bauer S, Pantel K, Fehm T, DETECT study group.
    Breast Cancer Res; 2012 Aug 15; 14(4):R118. PubMed ID: 22894854
    [Abstract] [Full Text] [Related]

  • 24. Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast Cancer.
    Mu Z, Benali-Furet N, Uzan G, Znaty A, Ye Z, Paolillo C, Wang C, Austin L, Rossi G, Fortina P, Yang H, Cristofanilli M.
    Int J Mol Sci; 2016 Sep 30; 17(10):. PubMed ID: 27706044
    [Abstract] [Full Text] [Related]

  • 25. Circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers combined with clinicopathological risk has potential to better predict recurrence in stage III breast cancer treated with neoadjuvant chemotherapy: a pilot study.
    Du KY, Wu S, Ma X, Liu Y.
    Breast Cancer Res Treat; 2024 Oct 30; 207(3):517-527. PubMed ID: 38990453
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer.
    Davis AA, Zhang Q, Gerratana L, Shah AN, Zhan Y, Qiang W, Finkelman BS, Flaum L, Behdad A, Gradishar WJ, Platanias LC, Cristofanilli M.
    Breast Cancer Res; 2019 Dec 04; 21(1):137. PubMed ID: 31801599
    [Abstract] [Full Text] [Related]

  • 33. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
    Jueckstock J, Rack B, Friedl TW, Scholz C, Steidl J, Trapp E, Tesch H, Forstbauer H, Lorenz R, Rezai M, Häberle L, Alunni-Fabbroni M, Schneeweiss A, Beckmann MW, Lichtenegger W, Fasching PA, Pantel K, Janni W, SUCCESS Study Group.
    BMC Cancer; 2016 Jul 07; 16():401. PubMed ID: 27387743
    [Abstract] [Full Text] [Related]

  • 34. Response Assessment With Molecular Characterization of Circulating Tumor Cells and Plasma MicroRNA Profiling in Patients With Locally Advanced Breast Cancer During Neoadjuvant Chemotherapy.
    Akkiprik M, Koca S, Uğurlu MÜ, Ekren R, Peker Eyüboğlu İ, Alan Ö, Erzik C, Güllü Amuran G, Telli TA, Güllüoğlu MB, Sezerman U, Yumuk PF.
    Clin Breast Cancer; 2020 Aug 07; 20(4):332-343.e3. PubMed ID: 32201164
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Validation of expression patterns for nine miRNAs in 204 lymph-node negative breast cancers.
    Jonsdottir K, Janssen SR, Da Rosa FC, Gudlaugsson E, Skaland I, Baak JP, Janssen EA.
    PLoS One; 2012 Aug 07; 7(11):e48692. PubMed ID: 23144930
    [Abstract] [Full Text] [Related]

  • 37. Androgen receptor expression in circulating tumor cells of patients with metastatic breast cancer.
    de Kruijff IE, Sieuwerts AM, Onstenk W, Jager A, Hamberg P, de Jongh FE, Smid M, Kraan J, Timmermans MA, Martens JWM, Sleijfer S.
    Int J Cancer; 2019 Aug 15; 145(4):1083-1089. PubMed ID: 30761532
    [Abstract] [Full Text] [Related]

  • 38. Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial.
    Gennari A, Foca F, Zamarchi R, Rocca A, Amadori D, De Censi A, Bologna A, Cavanna L, Gianni L, Scaltriti L, Rossi E, Facchinetti A, Martini V, Bruzzi P, Nanni O.
    Breast Cancer Res Treat; 2020 May 15; 181(1):61-68. PubMed ID: 32200486
    [Abstract] [Full Text] [Related]

  • 39. Prognostic relevance of viable circulating tumor cells detected by EPISPOT in metastatic breast cancer patients.
    Ramirez JM, Fehm T, Orsini M, Cayrefourcq L, Maudelonde T, Pantel K, Alix-Panabières C.
    Clin Chem; 2014 Jan 15; 60(1):214-21. PubMed ID: 24255082
    [Abstract] [Full Text] [Related]

  • 40. Circulating tumor cells following first chemotherapy cycle: an early and strong predictor of outcome in patients with metastatic breast cancer.
    Martín M, Custodio S, de Las Casas ML, García-Sáenz JÁ, de la Torre JC, Bellón-Cano JM, López-Tarruella S, Vidaurreta-Lazaro M, de la Orden V, Jerez Y, Márquez-Rodas I, Casado A, Sastre J, Díaz-Rubio E.
    Oncologist; 2013 Jan 15; 18(8):917-23. PubMed ID: 23873719
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 58.